Novartis to divest assets to Bausch + Lomb for $2.5B
Novartis has agreed to divest its front of eye ophthalmology assets to global health company Bausch + Lomb in a $2.5 billion deal, including $1.
Source: beckersasc.com
Stay updated with breaking news from Cular Surface Pain. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novartis has agreed to divest its front of eye ophthalmology assets to global health company Bausch + Lomb in a $2.5 billion deal, including $1.